6 / 18
CM 066: Nivolumab
primera linea
Atkinson V, Ascierto PA, Long GV, et al. Two-Year Survival and Safety Update in Patients With Treatment-Naïve Advanced Melanoma (MEL) Receiving Nivolumab or
Dacarbazine in CheckMate 066. Presented at Society for Melanoma Research (SMR) 2015 International Congress; November 18–21, 2015; San Francisco, California, USA